6533b82dfe1ef96bd129131e
RESEARCH PRODUCT
Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
Dario NicosiaAndrea CortegianiGiovanni MisseriAntonino FedericoIvan VignaPasquale Iozzosubject
lcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematologyIntravenous boluslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawActivated factor VIIpercutaneous tracheostomyMedicinepostoperatory bleedinglcsh:R5-920activated factor VIIFactor VIIbusiness.industrylcsh:RLow doserFVIIaGeneral MedicineThrombocytopeniaPercutaneous dilational tracheostomychemistry030220 oncology & carcinogenesisAnesthesiaPercutaneous tracheostomyRecombinant DNAlcsh:Medicine (General)businessdescription
Key Clinical Message In our case, the use of a low intravenous bolus dose of rFVIIa (recombinant factor VII activated; 15‐20 mcg/kg) was effective and uneventful in controlling late postprocedural PDT bleeding associated with thrombocytopenia that cannot be corrected and after all other treatments failed.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-04-01 | Clinical Case Reports |